Janux Therapeutics (JANX) Receivables - Other (2023 - 2025)
Janux Therapeutics (JANX) has disclosed Receivables - Other for 3 consecutive years, with $6.4 million as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Other rose 19.46% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 19.46% increase, with the full-year FY2025 number at $6.4 million, up 19.46% from a year prior.
- Receivables - Other was $6.4 million for Q4 2025 at Janux Therapeutics, up from $6.3 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $6.4 million in Q4 2025 to a low of $2.2 million in Q4 2023.
- A 3-year average of $4.9 million and a median of $5.4 million in 2024 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: surged 149.01% in 2024, then grew 19.46% in 2025.
- Janux Therapeutics' Receivables - Other stood at $2.2 million in 2023, then soared by 149.01% to $5.4 million in 2024, then rose by 19.46% to $6.4 million in 2025.
- Per Business Quant, the three most recent readings for JANX's Receivables - Other are $6.4 million (Q4 2025), $6.3 million (Q3 2025), and $5.7 million (Q2 2025).